Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
about
Targeting mTOR for the treatment of AML. New agents and new directionsDifferential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia.Autophagy: cancer's friend or foe?Autophagy as a therapeutic target in cancer.Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutationsThe regulation of class IA PI 3-kinases by inter-subunit interactions.Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia.Lentiviral vector-mediate ATG3 overexpression inhibits growth and promotes apoptosis of human SKM-1 cells.Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.Posttranscriptional regulation of the p85α adapter subunit of phosphatidylinositol 3-kinase in human leukemia cells.Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms.Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells.PI3K/AKT Signaling in CancerConstitutive Signaling by Aberrant PI3K in CancerTargeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.PI3K gain of function mutants phosphorylate PIP2 to PIP3The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis.
P2860
Q24617223-0090334A-C824-4A52-B5C7-919DFC4CC99AQ30492318-D8985D01-194F-4909-8F0E-B7A57F040CB8Q33493174-D45A64F4-5895-4B14-A56C-85998C4ED0EBQ33840360-DFC12F4A-34A6-4423-97F3-EC0248264C8BQ34024558-011A0798-51F2-41F4-9AEB-049513C2B493Q35124582-C3AE5989-78FB-4CFF-A49E-B7F700E651D8Q35146596-07A2095D-3E6C-419B-904F-F7D1DB10E605Q35591562-E3F859FB-335C-441C-B4D3-1B4E3ACA55ECQ36436853-8EA03089-AC89-491F-B8A9-9C2322EE5858Q36549790-4B7A4A96-EDC8-4455-901C-AA473F338062Q37764745-9539AFFB-33CA-4EF6-88B0-5EE7DA71ADCBQ38113583-06610FA0-8E51-4CD1-8407-436D4CCBEFDCQ39034685-8658724B-5433-449F-B286-9BA0266BD192Q39206146-B99850CD-B970-4469-9106-06FF3BB42F36Q39596672-15C1ACBB-310E-4977-9883-577CFEC2B184Q39631767-5A254B63-7308-47E3-83E7-ACC3E611362FQ39766760-E1516524-EB4A-4B3A-A9D7-B13F6D120574Q39853444-E98CE680-00EF-44F4-B322-901AFA5A7613Q43143677-EFDA98FA-7BD2-49BB-B09B-0AD9CD0BA073Q44172611-1163A85C-8FBE-4725-978A-DE3E077233DFQ45314383-D0F5C3A9-440A-489A-8212-96F4EA218ACAQ45314384-96D3109A-F549-40A3-AE97-DF76AA529A97Q47110143-BD2576C3-E840-4036-8818-6F7697A99432Q50288790-99510DE4-8B5B-441B-BF3E-90105CC990AFQ52727884-EE3FE109-6F1C-4ED5-9114-3CFB9A51A4F0
P2860
Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Mutations in the catalytic sub ...... ential to hematopoietic cells.
@en
type
label
Mutations in the catalytic sub ...... ential to hematopoietic cells.
@en
prefLabel
Mutations in the catalytic sub ...... ential to hematopoietic cells.
@en
P2093
P356
P1433
P1476
Mutations in the catalytic sub ...... tential to hematopoietic cells
@en
P2093
P2888
P304
P356
10.1038/ONC.2008.40
P407
P577
2008-03-03T00:00:00Z
P5875
P6179
1000852911